The objectives of this prospective, longitudinal multicenter study were to (1) examine the prognostic value of [18F]flortaucipir and [18F]RO948 tau PET in a large cohort (n = 1431) of individuals with AD dementia, mild cognitive impairment (MCI), or normal cognition; (2) perform a head-to-head comparison of tau PET with established magnetic resonance imaging (MRI) and amyloid PET markers for predicting future cognitive change; and (3) investigate whether age, sex, and/or APOE genotype modify the association between baseline tau PET and cognitive change over time. The gene discussed is MAPT; the disease is Cognitive impairment.